Question 1

What are the most cited papers from Italian Sarcoma Group?

Accepted Answer

The most cited paper from Italian Sarcoma Group is "Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups" (Alessandro Gronchi et al., 2020), with 264 citations. Next come "Neoadjuvant chemotherapy in high‐risk soft tissue sarcomas: A Sarculator‐based risk stratification analysis of the ISG‐STS 1001 randomized trial" (108) and "Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group" (96).

Question 2

Which research topics does Italian Sarcoma Group publish most on?

Accepted Answer

By volume in 2022-now: Bone Tumor Diagnosis and Treatments, Cancer Genomics and Diagnostics, Pharmacovigilance and Adverse Drug Reactions and Ethics in Clinical Research.

Question 3

Which fields of science does Italian Sarcoma Group work in?

Accepted Answer

In all years, 90% of research at Italian Sarcoma Group is in Health Sciences, 5% in Life Sciences. Its largest fields are Medicine (88%), Biochemistry, Genetics and Molecular Biology (4%), Economics, Econometrics and Finance (3%). It does 2.4× the world's share of Health Sciences.

Question 4

Is Italian Sarcoma Group's research output growing?

Accepted Answer

Output in 2022-2025 was 91% lower than in 2018-2021.